Circe Biomedical is committed to the development, production, and commercialization of novel bioartificial organs based on its proprietary mammalian cell and semi-permeable membrane technologies.

These technologies enable the company to:

		Isolate, purify, and preserve primary mammalian cells
		Fabricate semipermeable, biocompatible membranes designed to regulate the passage of selected molecules
		Design and develop novel biomedical systems incorporating these isolated cells and membranes to provide essential organ functions

Elizabeth Chen, President and Chief Executive Officer

Ted Owens, Chief Financial Officer

Shawn Cain, MS, Vice President, Operations 

Steve Andre, Director, Clinical Operations

Santosh Raina, Director, Quality Systems

Richard Kruger, Regulatory Consultant